Albany, NY -- (SBWIRE) -- 09/16/2013 -- GBI Research, the leading business intelligence provider, has released its latest research, “Multiple Sclerosis Therapeutics to 2019 Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth”. Currently there are a number of disease-modifying drugs in the Multiple Sclerosis (MS) market that are indicated for the treatment of relapsing forms of the disease, specifically reducing the frequency of disease relapses. The market is led by Copaxone, which achieved global sales of $4 billion in 2012.

Complete Report @ http://www.researchmoz.us/multiple-sclerosis-therapeutics-to-2019-treatment-diversification-increasing-efficacy-and-pipeline-innovation-combine-to-drive-growth-report.html

Over the forecast period 2012–2019, a variety of new drugs are due to enter the market that will offer a vast improvement in efficacy but also convenience, as many of these drugs are orally administered. Additionally, a high number of monoclonal Antibodies (mAbs) are due to enter the market and diversify it in terms of its portfolio for late stage or aggressive MS. All of these drugs have been shown to offer substantial improvements over current therapies. The price of these new therapies is expected to be high, particularly for the mAbs, but this is unlikely to hinder their uptake. As a result of this, as well as an overall increase in the treated population, GBI Research believes the global market has the potential to grow to a value of $17.9 billion by 2019.

Scope

A brief introduction to MS, including the disease’s history, pathogenesis, risk factors and diagnosis.

In-depth analysis of the eight major disease-modifying drugs for MS, including analyses of their safety, efficacy, treatment patterns and strengths/weaknesses. Includes a heat map comparing the drugs in terms of safety and efficacy.

Comprehensive review of the pipeline for MS therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets, as well as administration routes.

Additional analysis of pipeline drug clinical trials by phase, molecule type, trial size and trial duration.

Multi-scenario forecast model of the market, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology.

Discussion of the drivers and barriers for market growth or decay.

Browse All GBI Research Market Reports @ http://www.researchmoz.us/publisher/gbi-research-2.html

Reasons to buy

Understand the different levels of MS therapies, from early-stage/mild MS to late-stage/aggressive MS.

Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent.

Observe the trends in clinical trial duration and size amongst clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for multiple sclerosis therapeutics.

Observe the shift in clinical trial endpoints with clinical phase, and use this data to potentially influence any future developmental programs.

Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the multiple sclerosis therapeutics market.

Related Report

1) U.S.Cord Blood Banking Industry Report 2013-14

This section of the report(http://www.researchmoz.us/uscord-blood-banking-industry-report-2013-14-report.html) considers the impact of historical events, the importance of key findings and discoveries on market conditions, and rapidly changing aspects of the industry. It is a roadmap of where the cord blood banking industry has been, what has shaped it, and where it is going. With an understanding of these relevant market conditions, the subsequent sections of this report become “rooted” and relevant.

2) Endocarditis Global Clinical Trials Review, H2, 2013

GlobalData's clinical trial report,(http://www.researchmoz.us/endocarditis-global-clinical-trials-review-h2-2013-report.html) Endocarditis Global Clinical Trials Review, H2, 2013" provides data on the Endocarditis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Endocarditis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Endocarditis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

3) Fragile X Syndrome Global Clinical Trials Review, H2, 2013

Fragile X Syndrome (http://www.researchmoz.us/fragile-x-syndrome-global-clinical-trials-review-h2-2013-report.html)Global Clinical Trials Review, H2, 2013" provides data on the Fragile X Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Fragile X Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Fragile X Syndrome. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
http://www.researchmoz.us/
Blog: http://industryresearchnews.blogspot.com